Table 6 Sensitivity analysis II: risk of all cancers in ranitidine users compared with that in other H2RA users, including subjects who have switched between ranitidine and other H2RAs, in overall cohort and propensity matched cohort.
From: Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea
Exposure group | No. of patients | No. of events | 1000 Person years | Incidence rate per 1000 person years (95% CI) | Crude HR | Adjusted HR† |
|---|---|---|---|---|---|---|
Overall cohort | ||||||
Ranitidine | 61 560 | 2286 | 441 | 5.2 (5.0–5.4) | 1.07 (1.04–1.12) | 1.00 (0.96–1.05) |
Other H2RAs | 227 114 | 10,217 | 1970 | 5.2 (5.1–5.3) | Reference | Reference |
Propensity score matched cohort | ||||||
Ranitidine | 56 507 | 2208 | 422 | 5.2 (5.0–5.5) | 0.99 (0.93–1.05) | 0.98 (0.92–1.03) |
Other H2RAs | 56 507 | 2275 | 429 | 5.3 (5.1–5.5) | Reference | Reference |
